MetaCap

AC Immune SA (ACIU)

NASDAQ: ACIUHealthcareBiotechnologyUSD

2.57+0.05 (+1.98%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

ACIU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$255.53M
P/E (TTM)
—
Forward P/E
4.32
EPS (TTM)
-$0.55
Dividend yield
None
Ex-dividend date
—
52-week range
2.10 – 4.00
Day range
2.51 – 2.59
Volume / Avg
125.05K / 204.00K
Beta
—
Shares outstanding
99.43M
Next earnings
Nov 3, 2026

52-week range

$2.10$4.00

ACIU stock today

AC Immune SA (ACIU) closed at $2.57 on Oct 7, up 1.98% (+$0.05), versus the S&P 500's 0.22% decline. At this level, ACIU sits in the middle of its 52-week range of $2.10 to $4.00: 35.8% below the high, set on Oct 29, 2025 and 22.7% above the low. ACIU is down 18.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 28.4%.

AC Immune SA has posted a net loss over the last twelve months (EPS of -$0.55), so its P/E ratio is not meaningful. AC Immune SA's next earnings report is expected on Nov 3, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About AC Immune SA

Company profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Martin Zugel M.D., Ph.D.
Headquarters
Lausanne
Employees
90
IPO year
2016
Website
acimmune.com

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$8.52+231.52%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.35High $11.89

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 3, 2026
EPS estimate
$-0.22

ACIU news

All ACIU news

AC Immune SA peers

Healthcare sector
ACIU peer companies
CompanyPrice% ChgMarket capCompare
FATEFate Therapeutics Inc.2.15-6.11%$257.61Mvs ACIU
PALIPalisade Bio Inc.1.48-0.67%$257.92Mvs ACIU
UPBUpstream Bio Inc.4.61+0.44%$252.49Mvs ACIU
BCYCBicycle Therapeutics plc ADR3.73-1.58%$261.07Mvs ACIU
SABSSAB Biotherapeutics Inc.2.88-1.71%$262.04Mvs ACIU
ZNTLZentalis Pharmaceuticals Inc.2.55-4.49%$250.21Mvs ACIU
IMRXImmuneering Corporation Class A3.86+0.78%$249.73Mvs ACIU
NAUTNautilus Biotechnology Inc.1.96+10.73%$249.42Mvs ACIU

Indexes, lists and sector

Appears in lists

AC Immune SA stock FAQ

What is AC Immune SA's stock price today?

ACIU last traded at $2.57 as of Oct 7, 4:00 PM EDT, up 1.98% on the day. Prices are delayed at least 15 minutes.

When is AC Immune SA's next earnings date?

AC Immune SA is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.22.

Who is AC Immune SA's CEO?

Dr. Martin Zugel M.D., Ph.D. is the chief executive officer of AC Immune SA, which has about 90 employees.

What is the ACIU 52-week high?

The 52-week high for ACIU is $4.00 and the 52-week low is $2.10. The stock is currently 35.8% below its high.

Compare ACIU